2. Case: Mrs ME
86♀
Admitted 2/10/07 with 2/12 Hx worsening
mobility
• Leg weakness
• No altered sensation of pain
Fall noted 6/52 prior to admission
• ‘mechanical sounding’
• No LOC/HI/CP/palpitations/SOB
• Recalled incident
3. Case: Mrs ME
Intermittent confusion for 5/52 prior to
admission
• Treated for UTI (although no urinary signs or
symptoms)
4. Case: Mrs ME
PMH
• ‘Registered blind’
• Osteoporosis
• Angina
• Hypertension
• Asthma
• Episode of jaundice 40 yrs ago
8. Abnormal results
AMSE
• 8/10
• MMSE 20/28
• GDS 3/15
• i.e. not depressed
CT brain
• Moderate small vessel disease
• Small L occipital infarct
9. SHO WR 6/10/07
Thought pt had low mood d/w
consultant ref to Ψ liaison
• Felt that ‘new environment and poor eyesight
a significant factor in agitation’
11. SHO WR 11/10/07
Hallucinating
• “Horse woman of the year”
• Believed someone gave her eye drops (not
prescribed)
12. PD consultant review
“Tricky mixed picture which is difficult to
disentangle”
• Hallucinations
• Although ?Charles Bonnet in relation to reduced
eyesight
• Some reduced memory
• ?DLB but has cerebrovascular disease
• Parkinsonism – but not typical PD
• ‘tremor rather fine’
• ‘balance back’
Try madopar, ‘but suspect little to be gained
from medication’
14. Progress…
18/10/07 madopar commenced
22/10/07 more confused and
hallucinations worsening madopar
stopped & rivastigmine commenced
30/10/07 – paranoia and aggressive
15. Progress…
6/11/07 – hallucinations worse at night
quetiapine added
16/11/07 – mood even lower
venlafaxine added
Now awaiting community hospital bed
16. Diagnosis
Clinical features reflect anatomical
distribution of pathology rather than its
nature
Therefore subtle clinical features not
helpful
17. What is Dementia?
ICD-10 definition
1. A decline in memory to an extent that it interferes with everyday
activities, or makes independent living either difficult or impossible.
2. A decline in thinking, planning and organizing day-to-day things, again
to the above extent.
3. Initially, preserved awareness of the environment, including orientation
in space and time.
4. A decline in emotional control or motivation, or a change in social
behaviour, as shown in one or more of the following: emotional lability,
irritability, apathy or coarsening of social behaviour, as in eating, dressing
and interacting with others.
• Maj, M.. 2002., Dementia, Second Edition [online]. 2nd Edition. Wiley.
Available from:
http://mil.ingramdigital.com/Browse/open.asp?ID=10147&loc=Cover
15 November 2007
18. Wikipedia definition
Dementia is the progressive decline in
cognitive function due to damage or
disease in the brain beyond what might be
expected from normal ageing.
• http://en.wikipedia.org/wiki/Dementia
21. Nomenclature
Diffuse Lewy body Disease
Cortical Lewy body Disease
Lewy Body Dementia
Senile Dementia Of Lewy Type
Lewy Body Variant of Alzheimer's
Disease
Dementia with Lewy Bodies (preferred)
22. Dementia with Lewy Bodies
Describes several common disorders causing
dementia
The main features of these conditions are:
• development of dementia with features overlapping
with those of Alzheimer's disease
• development of features of Parkinson's disease
• fluctuation in severity of condition on a day-to-day
basis
• early development of hallucinations
23. Neuropathology
Degeneration of substantia nigra
Degeneration of the cortical areas of the
brain with many or all of the features
seen in Alzheimer's disease
Remaining nerve cells contain abnormal
structures called ‘Lewy bodies’
24. Lewy Bodies
Abnormal aggregation of proteins, including
• alpha-synuclein, neurofilament and ubiquitin
• PD
• Dementia with Lewy bodies
• MSA
• Amyotrophic lateral sclerosis
• Hallervorden-Spatz syndrome
Core, body, halo
Variations in shape
Synucleopathies
31. Alpha-synuclein
Abundant CNS protein
Composed of 140 amino acids
Alpha form of synuclein is the only form
capable of aggregating into fibrillar structures
in vitro
Beta-synuclein is not localized in Lewy
bodies, it may have a role in regulating
alpha-synuclein metabolism or aggregation
33. Normal role of alpha-synuclein
Synaptic plasticity
Negative regulation of dopamine
neurotransmission
Protection at nerve terminals during
injury
Trafficking of cargo in the ER/Golgi
complex
34. Alpha-synuclein in disease
‘Ubiquitinated’ with no loss of
proteasome function, suggesting there is
an excessive accumulation of alpha-
synuclein that overwhelms the
proteolytic machinery (Tofaris, et al.
2003). This may promote the formation
of Lewy bodies
35. Presenting Features DLB
Dementia normally presenting feature
Minority present with parkinsonism
Some with psychiatric disorder without dementia
Others with orthostatic hypotension, falls or transient
disturbances of consciousness
Sporadic (rarely familial)
36. Common Features
Fluctuation in cognitive performance and
functional ability
Variations in attention and level of
consciousness
Visual hallucinations in two-thirds
37. Gelder, Michael G.; Lopez-Ibor, Juan Jose; Andreasen, Nancy C..
2003., New Oxford Textbook of Psychiatry, Volume 1 [online]. New
Edition. Oxford University Press. Available from:
http://www.myilibrary.com/Browse/open.asp?ID=14714&loc=416 15
November 2007
38. Sensitive signs for ‘bedside’
diagnosis
Psychiatric vs. cognitive symptoms
• Hallucinations
• Delusions
Fluctuant cognitive state
39. Hallucinations
Repeated visual hallucinations are
present in about two-thirds of patients
• vivid, colourful, and sometimes fragmented
figures of people and animals
• often complex, detailed and rapidly moving
• can involve scenes and bizarre situations
• can start with misinterpretations and are usually
short
• often occur at night
• usually not distressing to the patient
40. Treatment
No cure
Cognitive symptoms
acetylcholinesterase inhibitors, such as
donepezil and rivastigmine
• May reduce psychiatric and motor symptoms
Rigidity levodopa
41. Summary
Third most common dementia
Central feature is progressive cognitive
decline
• Pronounced fluctuations
• Recurrent visual hallucinations
• Parkinsonism
Symptoms caused by Lewy Bodies
comprised of bits of alpha-synuclein
Editor's Notes
PATHOLOGICAL FEATURES
Several key areas of the brain undergo degeneration in this form of disease
There is degeneration of an area in the brain stem called the substantia nigra as would be seen in Parkinson's disease. Normally the substantia nigra is populated by nerve cells which contain a dark-brown pigment called neuromelanin. The cells of the substantia nigra are responsible for making the neurotransmitter dopamine. In both Parkinson's disease and Lewy body dementia these cells die and so the substantia nigra appears abnormally pale in comparison to normal. Remaining nerve cells contain abnormal structures called Lewy bodies. which are a pathological hallmark of the disease process.
Degeneration of the cortical areas of the brain with many or all of the features seen in Alzheimer's disease
Degeneration of the cortical areas of the brain with formation of abnormal structures inside nerve cells called cortical Lewy bodies which can be detected by immunochemical staining for the protein ubiquitin.
N
Dementia is usually, but not always, the presenting feature; a minority of patients present with parkinsonism alone, some with psychiatric disorder in the absence of dementia, and others with orthostatic hypotension, falls, or transient disturbances of consciousness. Fluctuation in cognitive performance and functional ability, which is based in variations in attention and level of consciousness, is the most characteristic feature of DLB It is usually evident on a day-to-day basis, and often apparent within much shorter periods. The marked amplitude between best and worst performance distinguishes it from the minor day-to-day variations that commonly occur in dementia of any aetiology. Repeated visual hallucinations are present in about two-thirds of patients. They take the form of vivid, colourful, and sometimes fragmented figures of people and animals,
Dementia with Lewy bodies (DLB) is one of the most common types of progressive dementia. The central feature of DLB is progressive cognitive decline, combined with three additional defining features: (1) pronounced “fluctuations” in alertness and attention, such as frequent drowsiness, lethargy, lengthy periods of time spent staring into space, or disorganized speech; (2) recurrent visual hallucinations, and (3) parkinsonian motor symptoms, such as rigidity and the loss of spontaneous movement. People may also suffer from depression. The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-synuclein protein -- inside the nuclei of neurons in areas of the brain that control particular aspects of memory and motor control. Researchers don’t know exactly why alpha-synuclein accumulates into Lewy bodies or how Lewy bodies cause the symptoms of DLB, but they do know that alpha-synuclein accumulation is also linked to Parkinson's disease, multiple system atrophy, and several other disorders, which are referred to as the "synucleinopathies." The similarity of symptoms between DLB and Parkinson’s disease, and between DLB and Alzheimer’s disease, can often make it difficult for a doctor to make a definitive diagnosis. In addition, Lewy bodies are often also found in the brains of people with Parkinson's and Alzheimer’s diseases. These findings suggest that either DLB is related to these other causes of dementia or that an individual can have both diseases at the same time. DLB usually occurs sporadically, in people with no known family history of the disease. However, rare familial cases have occasionally been reported.